This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

TRiUS Data Suggests That Testim® Significantly Improved Sexual Function In Hypogonadal Men

MALVERN, Pa., Nov. 3, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced the release of clinical practice data from the Testim Registry in the United States (TRiUS). This study showed that daily administration of Testim® 1% (testosterone gel) resulted in significantly improved sexual function and increased total testosterone levels in men with hypogonadism, often referred to as low testosterone. Sexual function assessments from TRiUS, which followed patients in clinical practice for a 12-month period, were published in the November issue of the Journal of Sexual Medicine.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

"These data are an important look at testosterone replacement therapy's (TRT) impact on sexual function in hypogonadal men," said Mohit Khera, M.D., Director of the Laboratory for Andrology Research at Baylor College of Medicine and lead study investigator.  "The improved level of sexual function seen in the study participants suggests that the increases of total testosterone achieved with TRT may correlate with the improvement in their self-reported sexual function."

Investigators assessed data from 271 TRiUS patients and evaluated the correlation between changes in the patients' Brief Male Sexual Function Inventory (BMSFI) scores and their mean total testosterone levels after 12 months of Testim therapy. The BMSFI assessed patients' self-reported sexual drive/libido, erectile function, ejaculatory function, and level of bother/sexual problems. After 12 months of TRT, mean total BMSFI scores significantly increased from baseline from 27.4 +/- 10.3 to 33.8 +/- 9.8 (P < 0.001) and mean total testosterone concentrations increased from 9.28 +/- 4.84 to 17.37 +/- 8.61 nmol/L (p<0.001). Regression analysis indicated that the increased total BMSFI score was significantly associated with increased total testosterone levels.

Significant improvement in sexual function from baseline scores was also seen in a subset of study participants concurrently using PDE5 inhibitors (for example, Viagra® and Cialis®) for erectile dysfunction (ED). Patients on PDE5 inhibitors had significantly lower baseline sexual function scores than other participants, but these scores improved after six and 12 months of TRT.  

Stock quotes in this article: AUXL 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs